0001375151-20-000002.txt : 20200103
0001375151-20-000002.hdr.sgml : 20200103
20200103161301
ACCESSION NUMBER: 0001375151-20-000002
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200102
FILED AS OF DATE: 20200103
DATE AS OF CHANGE: 20200103
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Smith Michael P
CENTRAL INDEX KEY: 0001355576
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-34962
FILM NUMBER: 20505471
MAIL ADDRESS:
STREET 1: 887 GREAT NORTHERN WAY
CITY: VANCOUVER
STATE: A1
ZIP: V5T 4T5
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ZOGENIX, INC.
CENTRAL INDEX KEY: 0001375151
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 205300780
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 5959 HORTON STREET, SUITE 500
CITY: EMERYVILLE
STATE: CA
ZIP: 94608
BUSINESS PHONE: (510) 550-8300
MAIL ADDRESS:
STREET 1: 5959 HORTON STREET, SUITE 500
CITY: EMERYVILLE
STATE: CA
ZIP: 94608
FORMER COMPANY:
FORMER CONFORMED NAME: ZOGENIX INC
DATE OF NAME CHANGE: 20060911
4
1
wf-form4_157808596439199.xml
FORM 4
X0306
4
2020-01-02
0
0001375151
ZOGENIX, INC.
ZGNX
0001355576
Smith Michael P
C/O ZOGENIX, INC.
5959 HORTON STREET, SUITE 500
EMERYVILLE
CA
94608
0
1
0
0
EVP, CFO, Treasurer & Sec.
Common Stock
2020-01-02
4
M
0
22500
10.35
A
23887
D
Common Stock
2020-01-02
4
S
0
14950
51.643
D
8937
D
Common Stock
2020-01-02
4
S
0
7550
52.0897
D
1387
D
Stock Option (Right to Buy)
10.35
2020-01-02
4
M
0
22500
0
D
2027-01-16
Common Stock
22500.0
67500
D
The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan.
The price reported in Column 4 is a weighted average price.These shares were sold in multiple transactions at prices ranging from $51.25 to $51.95, inclusive.The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, additional information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price.These shares were sold in multiple transactions at prices ranging from $51.96 to $52.50, inclusive.The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, additional information regarding the number of shares sold at each separate price within the range set forth in this footnote.
25% of the options vest on the first anniversary of the grant date, and the remaining options vest in equal monthly installments over the three year period thereafter, so that all of the options will be vested on the fourth anniversary of the grant date, subject to the Reporting Person's continued employment or service to the Company on each vesting date.
/s/ Thomas Doyle, Attorney-in-fact for Michael Smith
2020-01-03